Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Boyd

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|June 18, 2010
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II studyStephen A Schey, Gareth J Morgan, Karthik Ramasamy, et al.
Leukemia & Lymphoma|February 7, 2009
The impact of extramedullary disease at presentation on the outcome of myelomaPing Wu, Faith E Davies, Kevin Boyd, et al.
Pediatric Quality & Safety|April 8, 2024
Quality Improvement Project to Improve the Timeliness of Care for Children With Testicular Torsion in the Emergency DepartmentSri S Chinta, Matthew P Gray, Matthew Kopetsky, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
Experimental Gerontology|September 1, 2020
Txn2 haplodeficiency does not affect cochlear antioxidant defenses or accelerate the progression of cochlear cell loss or hearing loss across the lifespanMi-Jung Kim, Chul Han, Karessa White, et al.
Blood|April 28, 2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsTina Bagratuni, Ping Wu, David Gonzalez de Castro, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Elife|April 12, 2017
A metabolic switch controls intestinal differentiation downstream of <i>Adenomatous</i> polyposis coli (APC)Imelda T Sandoval, Richard Glenn C Delacruz, Braden N Miller, et al.
British Journal of Sports Medicine|June 18, 2016
Injury and illness in aquatic sport: how high is the risk? A comparison of results from three FINA World ChampionshipsAnnika Prien, Margo Mountjoy, Jim Miller, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|June 18, 2010
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II studyStephen A Schey, Gareth J Morgan, Karthik Ramasamy, et al.
Leukemia & Lymphoma|February 7, 2009
The impact of extramedullary disease at presentation on the outcome of myelomaPing Wu, Faith E Davies, Kevin Boyd, et al.
Pediatric Quality & Safety|April 8, 2024
Quality Improvement Project to Improve the Timeliness of Care for Children With Testicular Torsion in the Emergency DepartmentSri S Chinta, Matthew P Gray, Matthew Kopetsky, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
Experimental Gerontology|September 1, 2020
Txn2 haplodeficiency does not affect cochlear antioxidant defenses or accelerate the progression of cochlear cell loss or hearing loss across the lifespanMi-Jung Kim, Chul Han, Karessa White, et al.
Blood|April 28, 2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsTina Bagratuni, Ping Wu, David Gonzalez de Castro, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Elife|April 12, 2017
A metabolic switch controls intestinal differentiation downstream of <i>Adenomatous</i> polyposis coli (APC)Imelda T Sandoval, Richard Glenn C Delacruz, Braden N Miller, et al.
British Journal of Sports Medicine|June 18, 2016
Injury and illness in aquatic sport: how high is the risk? A comparison of results from three FINA World ChampionshipsAnnika Prien, Margo Mountjoy, Jim Miller, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
Pageof 5